quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:15:05·37d
ANALYSTRating
Tenax Therapeutics Inc. logo

Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

TENX· Tenax Therapeutics Inc.
Health Care
Original source

Companies

  • TENX
    Tenax Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 17UpdateCantor Fitzgerald$35.00
  • Sep 8UpdatePiper Sandler$20.00
  • Oct 24UpdateLeerink Partners$16.00
  • Oct 14UpdateGuggenheim$16.00
  • Sep 30UpdateWilliam Blair-

Related

  • SEC1d
    SEC Form DEFA14A filed by Tenax Therapeutics Inc.
  • SEC1d
    SEC Form DEF 14A filed by Tenax Therapeutics Inc.
  • SEC1d
    SEC Form 8-K filed by Tenax Therapeutics Inc.
  • PR1d
    Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
  • SEC22d
    SEC Form EFFECT filed by Tenax Therapeutics Inc.
  • SEC30d
    SEC Form S-3 filed by Tenax Therapeutics Inc.
  • SEC44d
    SEC Form 10-K filed by Tenax Therapeutics Inc.
  • SEC44d
    Tenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022